NYSE:RDY - Dr.Reddy's Laboratories Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$34.22 +0.39 (+1.15 %)
(As of 08/20/2018 04:00 PM ET)
Previous Close$33.83
Today's Range$33.79 - $34.35
52-Week Range$28.13 - $39.96
Volume199,500 shs
Average Volume394,379 shs
Market Capitalization$5.35 billion
P/E Ratio33.92
Dividend Yield0.82%
Beta0.22
Dr.ReddyDr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations for dermatology and neurology therapeutic areas. It also provides a portfolio of in-licensed dermatology products. As of March 31, 2017, this segment had 16 active products development programs pipeline that are in various stages of development. The company's therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, pain management, oncology, dermatology, urology, and nephrology. It has collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology; collaboration agreement with Merck Serono to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies; and strategic collaboration with Amgen Inc. for the commercialization of oncology and osteoporosis medicines. Dr. Reddy's Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.

Receive RDY News and Ratings via Email

Sign-up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:RDY
CUSIPN/A
Phone91-40-4900-2900

Debt

Debt-to-Equity Ratio0.20
Current Ratio1.64
Quick Ratio1.19

Price-To-Earnings

Trailing P/E Ratio33.92
Forward P/E Ratio25.35
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.20 billion
Price / Sales2.58
Cash Flow$2.2192 per share
Price / Cash15.42
Book Value$11.71 per share
Price / Book2.92

Profitability

EPS (Most Recent Fiscal Year)$1.01
Net Income$151 million
Net Margins9.41%
Return on Equity11.74%
Return on Assets6.52%

Miscellaneous

Employees23,524
Outstanding Shares165,830,000
Market Cap$5.35 billion

Dr.Reddy's Laboratories (NYSE:RDY) Frequently Asked Questions

What is Dr.Reddy's Laboratories' stock symbol?

Dr.Reddy's Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "RDY."

How were Dr.Reddy's Laboratories' earnings last quarter?

Dr.Reddy's Laboratories Ltd (NYSE:RDY) released its quarterly earnings data on Tuesday, May, 22nd. The company reported $0.28 EPS for the quarter. The business had revenue of $549.32 million for the quarter. Dr.Reddy's Laboratories had a net margin of 9.41% and a return on equity of 11.74%. View Dr.Reddy's Laboratories' Earnings History.

When is Dr.Reddy's Laboratories' next earnings date?

Dr.Reddy's Laboratories is scheduled to release their next quarterly earnings announcement on Tuesday, October, 30th 2018. View Earnings Estimates for Dr.Reddy's Laboratories.

What price target have analysts set for RDY?

3 brokerages have issued 12 month price targets for Dr.Reddy's Laboratories' shares. Their predictions range from $30.51 to $30.51. On average, they expect Dr.Reddy's Laboratories' stock price to reach $30.51 in the next twelve months. This suggests that the stock has a possible downside of 10.8%. View Analyst Price Targets for Dr.Reddy's Laboratories.

What is the consensus analysts' recommendation for Dr.Reddy's Laboratories?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dr.Reddy's Laboratories in the last year. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Dr.Reddy's Laboratories.

Who are some of Dr.Reddy's Laboratories' key competitors?

Who are Dr.Reddy's Laboratories' key executives?

Dr.Reddy's Laboratories' management team includes the folowing people:
  • Mr. Gunupati Venkateswara Prasad B.Sc. (Chem. Eng.), M.S. (Indl. Admn.), Co-Chairman, MD & CEO (Age 58)
  • Mr. Kallam Satish Reddy B.Tech., M.S., Chairman (Age 51)
  • Mr. Saumen Chakraborty B.Sc. (H), MBA-IIM, Pres, CFO and Global Head of Information Technology & Bus. Process Excellence (Age 57)
  • Dr. Sripada Chandrasekhar Mba., Ph.D., Pres & Global Head of HR (Age 61)
  • Dr. Kandiraju Venkata Sita Ram Rao B.Tech, M.E., Ph.D., Sr. VP & Bus. Head of PSAI Commercial Organization (Age 55)

Has Dr.Reddy's Laboratories been receiving favorable news coverage?

News articles about RDY stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Dr.Reddy's Laboratories earned a media and rumor sentiment score of 0.05 on Accern's scale. They also assigned news coverage about the company an impact score of 47.12 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View Recent Headlines for Dr.Reddy's Laboratories.

Who are Dr.Reddy's Laboratories' major shareholders?

Dr.Reddy's Laboratories' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Commonwealth Bank of Australia (1.06%), BlackRock Inc. (0.94%), Advisors Asset Management Inc. (0.52%), Dimensional Fund Advisors LP (0.50%), Renaissance Technologies LLC (0.35%) and First Trust Advisors LP (0.25%).

Which institutional investors are selling Dr.Reddy's Laboratories stock?

RDY stock was sold by a variety of institutional investors in the last quarter, including Hexavest Inc., Bank of Montreal Can, Legal & General Group Plc, Zurcher Kantonalbank Zurich Cantonalbank, Greenleaf Trust, Migdal Insurance & Financial Holdings Ltd. and Commerzbank Aktiengesellschaft FI.

Which institutional investors are buying Dr.Reddy's Laboratories stock?

RDY stock was bought by a variety of institutional investors in the last quarter, including Advisors Asset Management Inc., Renaissance Technologies LLC, Millennium Management LLC, BlackRock Inc., Dimensional Fund Advisors LP, NINE MASTS CAPITAL Ltd, Jane Street Group LLC and Acadian Asset Management LLC.

How do I buy shares of Dr.Reddy's Laboratories?

Shares of RDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dr.Reddy's Laboratories' stock price today?

One share of RDY stock can currently be purchased for approximately $34.22.

How big of a company is Dr.Reddy's Laboratories?

Dr.Reddy's Laboratories has a market capitalization of $5.35 billion and generates $2.20 billion in revenue each year. The company earns $151 million in net income (profit) each year or $1.01 on an earnings per share basis. Dr.Reddy's Laboratories employs 23,524 workers across the globe.

How can I contact Dr.Reddy's Laboratories?

Dr.Reddy's Laboratories' mailing address is 8-2-337 ROAD NO.3 BANJARA HILLS, HYDERABAD K7, 500-034. The company can be reached via phone at 91-40-4900-2900 or via email at [email protected]


MarketBeat Community Rating for Dr.Reddy's Laboratories (NYSE RDY)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  195 (Vote Outperform)
Underperform Votes:  276 (Vote Underperform)
Total Votes:  471
MarketBeat's community ratings are surveys of what our community members think about Dr.Reddy's Laboratories and other stocks. Vote "Outperform" if you believe RDY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/20/2018 by MarketBeat.com Staff

Featured Article: Investing in Growth Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel